If you haven’t seen it, a recent small study showed 100% effectiveness in eliminating stage II/III colorectal cancer:
https://www.onclive.com/view/dostarlimab-elicits-clinical-co…
Single-agent dostarlimab-gxly (Jemperli) elicited a clinical complete response (cCR) rate of 100% with no evidence of residual tumor among 14 patients with stage II/III mismatch repair–deficient (dMMR) locally advanced rectal cancer, according to data from a phase 2 trial (NCT04165772) presented at the 2022 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine.1,2
Yes, very small study, but also remarkable results. Obviously larger studies are required, but with 100% success, this is very positive news.